Psyence Biomedical Ltd.

The momentum for this stock is not very good. Psyence Biomedical Ltd. is not very popular among insiders. Tradey thinks it is not wise to invest in Psyence Biomedical Ltd..

News

Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care

Benzinga Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disorder.\n more…

Psyence Biomedical intiates first trial site in Australia for Phase IIb study

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Globe Newswire Patient screening to be initiated imminently; first subject expected to be randomized into the study in OctoberNEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM...\n more…

Psyence Biomedical to acquire drug developer Clairvoyant

Seeking Alpha - Healthcare Psyence Biomedical to acquire drug developer Clairvoyant...\n more…

Psyence Biomedical signs term sheet for acquisition of Clairvoyant

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Globe Newswire Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD...\n more…